Time will tell Nigel ...
who is right
after all we are in the last furlong
is buying with sustainability to maintain that practice the best policy to MAXIMUM TAX advantage
or not ...
but to do that you need a sound economic base !! able to withstand any effect because like Bermuda said
"That's a lot of money in one share"
but i do not play .... "what if"
i play "how can it fail"
synergy makes it a dead Cert |
probably had a lot of fun ..... but i didn't go fishing for Damp Squib 🤣 |
Sure it wasn't kindergarten....when you were 18 ? |
That's the martingale strategy gone mad Ruck ;-) |
no if you have £100k to invest you buy the shares at 20p or 10p or what ever
the risk profile is identical |
Lot more involved than folks think...
.
Put it this way...if you and ALL the happy-clappers on LSE worked together....you wouldn't pass the 11+ |
'risk dissipates with price'?What is the idiot talking about ? JeezI think it works something like this.....Buy £100k worth of shares at 20p. There is a risk of losing £100k. But, if you wait til they drop to 10p you can now only lose another £50k thereby you've halved your risk. You can go a step further and buy another £50k so you are now back to your original £100k negating the original risk. |
Turkey a damp squib is not a fish ...
its a firework that fizz's ... without the boom
🦃 chased by 🐋 |
You haven't the first semblance of stock market risk ..as every action and word you utter demonstrates. Your assessment of this stock has been WRONG at every turn.
.
Meanwhile Bitcoin soars higher.
One of the advantages of not being real...NO external influences WHATSOEVER.
.
The market is a place of irony...and contradiction. |
some times i do not want to add to much in the replies because its a lot more involved than folks think.
and i get moaned at for posting ........🤣 |
Killer whale ? Don't you mean damp squib,..
.
.
'risk dissipates with price'?
What is the idiot talking about ? Jeez |
also this Renal cell doublet is in "First line" treatment
its really important if your spending a lot of money on the trial to get the patients first rather than after a failure from another treatment
"the right setting" |
so you see getting the technical data with Doublet = Massive value added across the platform
we have synergy Modi1 and Pd-1
next stop
Simon Stage 1 ........ 19 patients doublet
if that does not work the trial stops (balanced posting) |
proof of further study requirements we saw in Iscib1
Scancell has also received MHRA correspondence requesting a preclinical mouse safety study with iSCIB1+ prior to resubmission of the amendment to the current trial protocol to include a new parallel cohort with the double CPIs with iSCIB1+.
Management do not see any potential issue with this regulatory request having previously completed identical studies with SCIB1. The iSCIB1+ cohort is now expected to start in Q1 2024. |
Thank you Marcus. That answers the one question that I hadat the back of my mind.
A major could pay, in the meantime, press on with renal a head and neck. |
Marcus, Many thanks for the reply. You seem to be of similar opinion to burble that it is largely down to money. |
defiantly ...
trouble is unless folks read the posts and take it in ... then they are worth diddly squat
Ruck's memory only lasted 24hrs, he had forgotten my reply and ask the same question again |
Good for everyone else to know maybe. Ovarian could be a promising trial with CPIs. |
marcus i had already replied to Ruck yesterday
Ruck is just being Ruck again ... |
our Killer whale is so smart it could lure a turkey for the kill. here is a killer whale baiting a bird so he can eat the bird ... |
Just looking on LSE re Ruck`s question;
Q
"So what happened to the other two targets? Particularly the ovarian patient(s) who had promising results. Have there been official announcements from the company or have they just been quietly dropped?"
A.
Check points are not approved for Ovarian so they would cost Scancell a fortune to try that combination. Big pharma will probably try it when licensed.
CTLA-4 and PD-1 is approved for Renal RCC, PD-1 for head & neck so push ahead with those two initially.
Head & Neck is a cold tumour so these results have been excellent.
Doublet will probably work better in H&N too.
(HNSCC tissues are in an immunosuppressive state, with fewer lymphocytes, natural killer (NK) cells and specific antigens than normal tissues. Thus, this cancer type is called a “cold tumour”. HNSCC can escape immune surveillance through different mechanisms.) |
oh no ... not two types of vaccine in one again ....
must be something to do with the "one immune system" |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
